252 related articles for article (PubMed ID: 23123670)
21. Initiation of peritoneal dialysis in the first weeks after catheter insertion: A comparison of a neutral-pH, low-GDP PD fluid and a conventional PD fluid
.
Farhat K; van Ittersum FJ; Ter Wee PM; Paauw NJ; Beelen RHJ; Douma CE
Clin Nephrol; 2018 Feb; 89(2):75-82. PubMed ID: 28992851
[TBL] [Abstract][Full Text] [Related]
22. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
23. Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study.
Fang W; Mullan R; Shah H; Mujais S; Bargman JM; Oreopoulos DG
Perit Dial Int; 2008; 28(1):35-43. PubMed ID: 18178946
[TBL] [Abstract][Full Text] [Related]
24. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
Nephrol Dial Transplant; 2012 Dec; 27(12):4445-53. PubMed ID: 22859794
[TBL] [Abstract][Full Text] [Related]
25. New animal models for encapsulating peritoneal sclerosis--role of acidic solution.
Nakamoto H; Imai H; Ishida Y; Yamanouchi Y; Inoue T; Okada H; Suzuki H
Perit Dial Int; 2001; 21 Suppl 3():S349-53. PubMed ID: 11887851
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
27. "Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?
Misra PS; Nessim SJ; Perl J
Semin Dial; 2017 Mar; 30(2):164-173. PubMed ID: 28251697
[TBL] [Abstract][Full Text] [Related]
28. The glucose degradation product methylglyoxal induces immature angiogenesis in patients undergoing peritoneal dialysis.
Nakano T; Kumiko T; Mizumasa T; Kuroki Y; Tsuruya K; Kitazono T
Biochem Biophys Res Commun; 2020 May; 525(3):767-772. PubMed ID: 32147098
[TBL] [Abstract][Full Text] [Related]
29. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.
Ayuzawa N; Ishibashi Y; Takazawa Y; Kume H; Fujita T
Perit Dial Int; 2012; 32(2):159-67. PubMed ID: 21804136
[TBL] [Abstract][Full Text] [Related]
30. No significant differences in peritoneal fluid handling in children using PH-neutral or acidic solutions.
Nourse P; van de Kar NC; Willems HL; Schröder CH
Perit Dial Int; 2006; 26(5):587-92. PubMed ID: 16973515
[TBL] [Abstract][Full Text] [Related]
31. The influence of bicarbonate/lactate-buffered PD fluids on N{ε}-(carboxyethyl)lysine and N{ε}-(carboxymethyl)lysine in peritoneal effluent.
Cnossen TT; Gladziwa U; van de Kerkhof JJ; Schalkwijk CG; Scheijen J; van Amersfoort J; Moret K; Beerenhout CH; Kooman JP
Perit Dial Int; 2011; 31(2):189-93. PubMed ID: 20671103
[TBL] [Abstract][Full Text] [Related]
32. Associations Between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the
Nataatmadja MS; Johnson DW; Pascoe EM; Darssan D; Hawley CM; Cho Y;
Perit Dial Int; 2018; 38(5):349-355. PubMed ID: 30087174
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions.
Cooker LA; Luneburg P; Holmes CJ; Jones S; Topley N;
Perit Dial Int; 2001; 21 Suppl 3():S102-7. PubMed ID: 11887802
[TBL] [Abstract][Full Text] [Related]
34. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin.
Posthuma N; ter Wee PM; Niessen H; Donker AJ; Verbrugh HA; Schalkwijk CG
Perit Dial Int; 2001; 21(1):43-51. PubMed ID: 11280495
[TBL] [Abstract][Full Text] [Related]
35. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.
Haas S; Schmitt CP; Arbeiter K; Bonzel KE; Fischbach M; John U; Pieper AK; Schaub TP; Passlick-Deetjen J; Mehls O; Schaefer F
J Am Soc Nephrol; 2003 Oct; 14(10):2632-8. PubMed ID: 14514742
[TBL] [Abstract][Full Text] [Related]
36. Update on mechanisms of ultrafiltration failure.
Kim YL
Perit Dial Int; 2009 Feb; 29 Suppl 2():S123-7. PubMed ID: 19270200
[TBL] [Abstract][Full Text] [Related]
37. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
38. Peritoneal dialysis and inflammation.
Velloso MS; Otoni A; de Paula Sabino A; de Castro WV; Pinto SW; Marinho MA; Rios DR
Clin Chim Acta; 2014 Mar; 430():109-14. PubMed ID: 24333488
[TBL] [Abstract][Full Text] [Related]
39. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions.
Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R
Perit Dial Int; 2000; 20(6):643-51. PubMed ID: 11216553
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis and treatment of peritoneal membrane failure.
Saxena R
Pediatr Nephrol; 2008 May; 23(5):695-703. PubMed ID: 17891546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
